realtime dynamix™: inflammatory bowel disease us q3 2017 · realtime dynamix™: inflammatory...
TRANSCRIPT
RealTime Dynamix™: Inflammatory Bowel Disease US Q3 2017
Remicade is considered by many as the go-to agent for treating IBD (Crohn’s disease and Ulcerative
Colitis), but the introduction and adoption of TNF-inhibiting biosimilars is starting to shake up the IBD
biologics market, according to RealTime Dynamix™: Inflammatory Bowel Disease US Q3, a survey of
103 US gastroenterologists fielded in August 2017. Highlights from this report:
Though use of the available infliximab biosimilars (Pfizer’s Inflectra and Merck/Samsung Bioepis’ Renflexis) is on
the rise and is projected to increase, US gastroenterologists are still on the fence regarding use of biosimilars.
However, as additional TNF inhibiting biosimilars become available, such as, Sandoz’s Erelzi (etanercept),
Amgen’s Amjevita (adalimumab), and Boehringer Ingelheim’s recently approved Cyltezo (adalimumab), it is
anticipated that insurance mandates for biosimilar use will become increasingly common.
Result of Contact from Pharmacist/Insurance Company Regarding Inflectra
Statement Agreement Levels
“I think the availability of biosimilars for IBD is a good thing for patients.”
“As more TNF biosimilars become available, the use of alternative MOAs will increase.”
The leading barrier to increased use of infliximab biosimilars appears to be apathy rather than clinical concerns. GIs report that in the majority of cases they are not being pushed to change.
19% of respondents indicated another result, including “starting
new patients on Inflectra” and “patients will be switched soon”
RealTime Dynamix™: IBD US is a quarterly report series providing insights about the evolving IBD market. Participating gastroenterologists are recruited from the Spherix Network, a proprietary panel of more than 400 gastroenterologists managing at least 50 patients with IBD. For more information contact: [email protected]
14%
20%
Percent of Gastroenterologists Contacted by a Pharmacist/Insurance Company Regarding Use
of Inflectra Over Branded Remicade
As payer pressure is likely to increase, six month projections
of the CD and UC biologic market reveal continued erosion
of the leading TNF brands, in favor of significant gains for
biosimilars and biologics with alternative MOAs.
OVERVIEW
Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), and Crohn’s
Disease (CD) currently affects the lives of approximately 1.6 million
Americans. The use of biologics has changed the face of treatment for
moderate-to-severe IBD patients. However, recent launches, an active
pipeline, and the introduction of biosimilars present an opportunity for
major future shifts in the IBD landscape.
RealTime Dynamix™: IBD (US) report series provides a detailed and
timely look at current and future trends in the IBD market, and the
effects of the future shifting landscape. The quarterly releases allow for
close monitoring and trending of key performance metrics. In addition to
the fixed trended measures, the report also includes variable content
addressing key current issues updated quarterly. The rapid field-to-insight
turnaround time, highly relevant content, and unparalleled knowledge of
the IBD market make this an essential tool for companies competing in
the space, as well as those with near term plans to enter it.
SAMPLE & METHODOLOGY
The report is based on an online survey of ~100 US gastroenterologists
and is fielded on a quarterly basis. Respondents are recruited from the
Spherix Network, a proprietary group of gastroenterologists in clinical
practice meeting quality screening criteria. Our relationship with this
network leads to more engaged respondents resulting in higher quality
output.
KEY QUESTIONS ANSWERED
What are the adoption and share trends for Stelara since the late
2016 launch and what products are losing to this new entrant?
How prominent is off-label Stelara prescribing in UC?
What is the ongoing trajectory of Entyvio in the face of new
competition from Stelara?
How is the adoption of alternative MOAs changing the practice of
sequencing two TNFs?
What are key barriers across brands?
How do key IBD brands perform on select attributes?
How is patient preference guiding brand choice?
To what degree will biosimilar agents off-set the TNF-inhibitors and
how is the market leading biologic, Remicade, being impacted by
Inflectra?
What can new entrants learn from the current payer access/barriers
for inline brands in order to plan for successful launches?
Products Profiled
Commercial Products
AbbVie’s Humira (adalimumab), Takeda’s Entyvio (vedolizumab), Janssen’s Remicade (infliximab) and Stelara (ustekinumab), UCB’s Cimzia (certolizumab), Biogen’s Tysabri (natalizumab), Pfizer’s Inflectra (infliximab biosimilar), Merck’s Renflexis (infliximab biosimilar)
Pipeline Agents
Roche/Genentech’s etrolizumab, Gilead’s filgotinib, Celgene’s mongersen, ozanimod and Otezla (apremilast),& Xeljanz (tofacitinib)
Key Dates
Q1 March
Q2 May
Q3 August
Q4 November
Note: a three day embargo is placed on delivery to
non-manufacturers allowing clients time to digest the
findings before public dissemination
Deliverables
PowerPoint report
Frequency Tables & Summary Statistics
On-site presentation
Proprietary questions (for purchasers of the annual series)
Related Reports 2017
RealWorld Dynamix™: Biologic Switching in IBD US
RealTime Dynamix™: IBS US
Pricing
$29,500 single quarterly wave
$89,500 annual series of four reports
To order or to get more information, please contact
Inflammatory Bowel Disease (US)